OptimizeRx Performance degli utili passati
Criteri Il passato verificati 3/6
Gli utili di OptimizeRx sono diminuiti a un tasso medio annuo di -22.6%, mentre il settore Healthcare Services ha visto gli utili crescere a un tasso medio annuo di 20.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 16.8%. Il ritorno sul capitale proprio di OptimizeRx è 4% e ha margini netti di 4.7%.
Informazioni chiave
-22.62%
Tasso di crescita degli utili
-22.00%
Tasso di crescita dell'EPS
| Healthcare Services Crescita del settore | 1.72% |
| Tasso di crescita dei ricavi | 16.77% |
| Rendimento del capitale proprio | 4.00% |
| Margine netto | 4.69% |
| Prossimo aggiornamento sugli utili | 12 May 2026 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Aggiornamento dell'analisi • May 01
OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential
The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.
Aggiornamento dell'analisi • Apr 17
OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside
Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.Aggiornamento dell'analisi • Apr 02
OPRX: Profit Focus And Buybacks Will Support Future Share Upside
Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.Aggiornamento dell'analisi • Mar 19
OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential
Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.Aggiornamento dell'analisi • Mar 05
OPRX: Expanded Point Of Care Network Will Support Further Upside
Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.
Aggiornamento dell'analisi • Feb 19
OPRX: New Data Partnerships Will Support Long Term Earnings Power
Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).Aggiornamento dell'analisi • Feb 05
OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power
Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.Aggiornamento dell'analisi • Jan 21
OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside
Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.Aggiornamento dell'analisi • Jan 07
OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power
Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.Aggiornamento dell'analisi • Dec 24
OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships
Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.Aggiornamento dell'analisi • Dec 09
OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside
Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.Aggiornamento dell'analisi • Nov 25
OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum
OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.Articolo di analisi • Nov 23
OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders won't be pleased to see that the share price has had a very rough...Aggiornamento dell'analisi • Nov 08
OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward
OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.Articolo di analisi • Oct 07
Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Aug 27
Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?
Key Insights OptimizeRx's estimated fair value is US$28.97 based on 2 Stage Free Cash Flow to Equity OptimizeRx's...Aggiornamento dell'analisi • Aug 15
Pharmaceutical Digital Engagement Will Unlock Future Value
Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.Articolo di analisi • May 09
Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
OptimizeRx Corporation ( NASDAQ:OPRX ) shares have continued their recent momentum with a 33% gain in the last month...
Nuova analisi • Apr 08
A Subscription Model And EHR Network Will Reshape Healthcare
Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Articolo di analisi • Apr 06
Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, OptimizeRx fair value estimate is US$6.02 Current share price...Articolo di analisi • Mar 08
We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Feb 14
At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
OptimizeRx Corporation ( NASDAQ:OPRX ), is not the largest company out there, but it received a lot of attention from a...Articolo di analisi • Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders are no doubt pleased to see that the share price has bounced 30% in...Articolo di analisi • Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Articolo di analisi • Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
OptimizeRx Corporation ( NASDAQ:OPRX ) shares have continued their recent momentum with a 36% gain in the last month...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come OptimizeRx guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Dec 25 | 109 | 5 | 57 | 0 |
| 30 Sep 25 | 110 | 0 | 60 | 0 |
| 30 Jun 25 | 105 | -10 | 59 | 0 |
| 31 Mar 25 | 94 | -15 | 59 | 0 |
| 31 Dec 24 | 92 | -20 | 61 | 0 |
| 30 Sep 24 | 88 | -24 | 59 | 0 |
| 30 Jun 24 | 83 | -18 | 58 | 0 |
| 31 Mar 24 | 78 | -18 | 56 | 0 |
| 31 Dec 23 | 72 | -18 | 54 | 0 |
| 30 Sep 23 | 63 | -14 | 52 | 0 |
| 30 Jun 23 | 62 | -14 | 52 | 0 |
| 31 Mar 23 | 62 | -14 | 52 | 0 |
| 31 Dec 22 | 62 | -11 | 49 | 0 |
| 30 Sep 22 | 63 | -10 | 46 | 0 |
| 30 Jun 22 | 64 | -7 | 43 | 0 |
| 31 Mar 22 | 64 | -3 | 39 | 0 |
| 31 Dec 21 | 61 | 0 | 33 | 0 |
| 30 Sep 21 | 57 | 1 | 30 | 0 |
| 30 Jun 21 | 52 | 1 | 26 | 0 |
| 31 Mar 21 | 47 | -1 | 23 | 0 |
| 31 Dec 20 | 43 | -2 | 23 | 0 |
| 30 Sep 20 | 34 | -6 | 22 | 0 |
| 30 Jun 20 | 29 | -7 | 21 | 0 |
| 31 Mar 20 | 27 | -5 | 20 | 0 |
| 31 Dec 19 | 25 | -3 | 17 | 0 |
| 30 Sep 19 | 24 | -1 | 15 | 0 |
| 30 Jun 19 | 24 | 1 | 13 | 0 |
| 31 Mar 19 | 22 | 0 | 12 | 0 |
| 31 Dec 18 | 21 | 0 | 11 | 0 |
| 30 Sep 18 | 19 | 0 | 10 | 0 |
| 30 Jun 18 | 16 | -1 | 9 | 0 |
| 31 Mar 18 | 14 | -1 | 8 | 0 |
| 31 Dec 17 | 12 | -2 | 7 | 0 |
| 30 Sep 17 | 10 | -2 | 7 | 0 |
| 30 Jun 17 | 9 | -2 | 6 | 0 |
| 31 Mar 17 | 8 | -2 | 6 | 0 |
| 31 Dec 16 | 8 | -2 | 6 | 0 |
| 30 Sep 16 | 7 | -2 | 2 | 0 |
| 30 Jun 16 | 8 | -1 | 1 | 0 |
| 31 Mar 16 | 7 | -1 | 1 | 0 |
| 31 Dec 15 | 7 | -1 | 1 | 0 |
| 30 Sep 15 | 7 | 0 | 1 | 0 |
| 30 Jun 15 | 7 | 0 | 1 | 0 |
Guadagni di qualità: OPRX ha guadagni di alta qualità.
Margine di profitto in crescita: OPRX è diventata redditizia in passato.
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: OPRX è diventata redditizia negli ultimi 5 anni, aumentando i guadagni del -22.6% all'anno.
Accelerare la crescita: OPRX è diventata redditizia nell'ultimo anno, rendendo difficile confrontare il tasso di crescita degli utili con la media quinquennale.
Guadagni vs Settore: OPRX è diventata redditizia nell'ultimo anno, rendendo difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Healthcare Services ( 27.3% ).
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 4% ) di OPRX è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/07 06:03 |
| Prezzo dell'azione a fine giornata | 2026/05/07 00:00 |
| Utili | 2025/12/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
OptimizeRx Corporation è coperta da 12 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Constantine Davides | Citizens JMP Securities, LLC |
| Eric Martinuzzi | Lake Street Capital Markets, LLC |